Industries > Pharma > Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis

PUBLISHED: 22 March 2017
PAGES: 200
PRODUCT CODE: PHA0178
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0178 Categories: ,

The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 200-page report you will receive 89 tables and 50 figures – all unavailable elsewhere.

The 200-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

Report Scope
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2017-2027

• Submarket forecasts from 2017-2027:
 – Biologics
 – Aminosalicylates
 – Antibiotics
 – Corticosteroids
 – Immunomodulators

• Revenue forecast from 2017-2027 for 17 leading products:
 – Humira
 – Remicade
 – Lialda
 – Asacol
 – Pentasa
 – Xifaxan
 – Cimzia
 – Tysabri
 – Simponi
 – Canasa/Salofalk
 – Entyvio
 – Apriso
 – Medrol
 – Neoral
 – Entocort
 – Uceris
 – Azulfidine

Revenue forecasts from 2017-2027 for 11 countries:
 – US
 – Japan
 – Germany, France, UK, Spain and Italy (EU5)
 – Brazil, Russia, India and China (BRIC)

Discussions on research and development, including drug candidates in these classes:
 – Interleukin (IL) inhibitors
 – Cell-adhesion molecule (CAM) inhibitors
 – TNF-alpha inhibitors
 – Stem cell therapies
 – JAK inhibitors
 – Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors influencing that industry and market (STEP)

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Inflammatory Bowel Diseases Market Analysis: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

    Download sample pages

    Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

      Latest Pharma news

      Visiongain Publishes Antibiotics Market Report 2023-2033

      The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

      The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

      The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Human Microbiome Market Report 2023-2033

      The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

      30 January 2023

      READ